EverSource Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

EverSource Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1K	Sell	1,170 -124	-10%	-$1.67K	﹤0.01%	2561
2026 Q1	$16.3K	Buy	1,294 +146	+13%	+$1.96K	﹤0.01%	2631
2025 Q4	$18.1K	Hold	1,148	–	–	﹤0.01%	2451
2025 Q3	$13.7K	Sell	1,148 -5	-0.4%	-$40	﹤0.01%	2628
2025 Q2	$8.72K	Buy	1,153 +1,013	+724%	+$6.09K	﹤0.01%	2889
2025 Q1	$773	Buy	140 +110	+367%	+$679	﹤0.01%	3321
2024 Q4	$173	Buy	+30	New	+$288	﹤0.01%	3455
2023 Q3	–	Sell	-68	Closed	-$1.46K	–	2551
2023 Q2	$1.46K	Buy	+68	New	+$2K	﹤0.01%	2108
2022 Q2	–	Sell	-38	Closed	-$3K	–	1760
2022 Q1	$3K	Hold	38	–	–	﹤0.01%	1408
2021 Q4	$3K	Buy	+38	New	+$2.98K	﹤0.01%	1411

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EverSource Wealth Advisors's ENTA Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Enanta Pharmaceuticals (ENTA) stake by 9.6% in Q2 2026, selling an estimated $1.67K and leaving 1,170 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

EverSource Wealth Advisors first reported a position in ENTA in Q4 2021 and has held it in 10 quarters since. The position peaked at $18.1K in Q4 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

EverSource Wealth Advisors held 1,170 shares of Enanta Pharmaceuticals worth $17.1K as of Q2 2026.
EverSource Wealth Advisors sold 124 Enanta Pharmaceuticals shares in Q2 2026, an estimated $1.67K.
Enanta Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2561 holding.
EverSource Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
EverSource Wealth Advisors's Enanta Pharmaceuticals position peaked at $18.1K in Q4 2025.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.